Cipla has received a reaffirmed ‘BUY’ rating from Prabhudas Lilladher following a pivotal regulatory development—the USFDA approval of its generic version of Abraxane (gAbraxane).
Prabhudas Lilladher has issued a ‘BUY’ recommendation for Federal Bank, setting a target price of Rs. 210. The bank’s medium-term strategy, articulated by MD & CEO Mr.